During the last few years, most major disease phenotypes have been studied through genome-wide association mapping. This has been a remarkably successful enterprise, resulting in the discovery of more than 500 validated SNP-phenot...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MTM2011-26515
MODELOS ESTADISTICOS, ALGORITMOS Y HERRAMIENTAS BIOINFORMATI...
28K€
Cerrado
PID2019-108096RB-C22
APROXIMACIONES BASADAS EN REDES PARA ASISTIR AL DIAGNOSTICO...
121K€
Cerrado
HAP-PHEN
From haplotype to phenotype a systems integration of alleli...
2M€
Cerrado
SAF2011-30391
DETECCION DE VARIANTES GENETICAS Y ESTRUCTURALES DE MANERA R...
67K€
Cerrado
BIO2014-57314-REDT
COMPRENSION, PREDICCION Y VALIDACION DEL FENOTIPO DE LAS MUT...
25K€
Cerrado
GENOMICMEDICINE
Towards evidence based genomic medicine filling the evidenc...
1M€
Cerrado
Información proyecto NEXTGENE
Líder del proyecto
AARHUS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
During the last few years, most major disease phenotypes have been studied through genome-wide association mapping. This has been a remarkably successful enterprise, resulting in the discovery of more than 500 validated SNP-phenotype associations. Yet, these associations do not explain all the heritability of many common genetic diseases and it is not at all clear how they exert their effect at the cell level. Furthermore, current genome-wide association studies are designed to only find common polymorphisms associated with diseases, and they have very limited ability to detect rare variants and variants that interact with each other to cause a given disease phenotype. In the near future disease mapping projects will have access to full genome sequencing. Our limitations will therefore not be lack of information about the genetic differences but our ability to analyse very high dimensional data in a statistically powerful way, manage the data, and last, but not least, to interpret these in relation to complex phenotypes. Next generation disease mapping therefore calls for methods that can handle complete genetic information and relate it to complex biological information on the disease phenotypes. We propose to do research into new methods that can find more variants contributing to disease by explicitly modelling their interaction and combine the statistical signal contributed by several rare variants. To do this we need methods that can handle the large scale sequencing data and we need systems level approaches that make explicit models of each phenotype (disease) under consideration. The outcome should be a more thorough understanding of the cellular changes that lead to disease and how certain genetic variants contribute.